Planning a Schedule M/WHO GMP Upgrade? You May Be Eligible for Government Incentives of Up to ₹2 Crore
Find Out Whether Your Project Is Ready for Revamped of Pharmaceutical Technology Upgradation Assistance Scheme Before You Invest Another Rupee.
Is This You?
The Challenge
Many eligible pharmaceutical manufacturers encounter delays, uncertainty, and missed opportunities due to the complexities involved in project planning, documentation, technical evaluation, sanction processes, claim submissions, and fund disbursement procedures.
Project Planning
Documentation
Subsidy evaluation
Sanction Processes
Claim Submissions
Fund Disbursement
Why These
Challenges Occur
Government incentive schemes operate within defined eligibility criteria, compliance requirements, and budgetary frameworks. Without proper planning and timely preparation, businesses may face avoidable delays, incomplete documentation, or reduced readiness during the evaluation process.
Defined Eligibility
Criteria
Strict guidelines must be met for consideration.
Compliance
Requirements
Multiple regulations ensure transparency and accountability.
Budgetary
Frameworks
Schemes operate within fixed budgets and timelines.
Timely Preparation
is Essential
Early planning reduces risk of delays and improves readiness.
Avoid the Mistakes That Delay Otherwise Eligible Projects
Even eligible pharmaceutical manufacturers can experience delays or missed opportunities due to avoidable planning and execution issues.
Common Challenges We Frequently Observe
Wrong Investment
Timing
Starting investments without understanding eligibility timelines can create complications.
Non-Eligible
Machinery
Certain machinery or components may not align with scheme guidelines.
Missing
Documentation
Incomplete or inadequate documentation can slow down assessments and approvals.
Wrong Cost
Allocation
Improper cost classification and allocation may affect how investments are evaluated.
Delayed
Claim
Delays in application, claim, or follow-up processes can lead to unnecessary setbacks.
Poor Project
Planning
Lack of structured planning leads to uncertainty, execution gaps and lower project readiness.
How Uplift Financial Supports Your RPTUAS Journey
UPLIFT financial supports pharmaceutical manufacturers with strategic guidance, execution support, and advisory services throughout the entire RPTUAS journey—from initial project assessment and planning to documentation, application support, sanction assistance, and claim-related processes.- till the realization of funds in client’s account
Our objective is to help Pharma manufacturers improve project readiness, navigate procedural complexities, and make informed decisions at every stage of the process.
Proven Expertise.
Real Impact.
Trusted by pharmaceutical manufacturers across India. We deliver complete solutions to support compliance, strategic planning, and successful project outcomes.
Active Projects
Crore Successfully Delivered
Projects Successfully Sanctioned
Expected in Upcoming SSC
Ready for Sanction when processing resumes.
RPTUAS Eligibility: Do You Qualify?
You Can Apply If:
-
You have an existing drug manufacturing unit- operational since last 3 years
-
You make formulations, APIs- Bulk Drugs too
-
Average turnover is between 1 crore to ₹500 crore (last 3 years)
-
You are planning / upgrading / upgradation is done as per Revised Schedule M/ WHO GMP compliance guidelines
-
Investment made after 1st January 2024
-
Valid Drug Manufacturing License under Drugs and Cosmetics Act, 1940
You Cannot Apply If:
-
You are a new unit (not yet operational or less than 3 years)
-
Turn over is less then 1 crore or more than 500 crore
-
You are only a trader (must be manufacturer)
-
You already received a similar subsidy for the same investment
Real Projects. Real Impact.
We are proud to support pharmaceutical manufacturers across India in their RPTUAS journey — from planning to claim Disbursement.
Tablet Manufacturing
Unit
-
Applied
-
Approved
-
Successfully Assisted
-
Claim realized in clients account
Injectables
Manufacturing Facility
-
Schedule M Upgrade
-
Documentation Completed
-
Claim Support
-
Ongoing Advisory Support
API Manufacturing
Company
-
Expansion Strategy Support
-
Approved Application
-
Claim Assistance
-
Continuous Handholding
Pharmaceutical Formulations
Manufacturer
-
Investment Planning
-
Documentation Support
-
Application Assistance
-
Compliance Guidance
WHO-GMP Upgradation
Project
-
Gap Assessment Completed
-
Documentation & Technical Support
-
Application Successfully Filed
-
Advisory Through Evaluation
Schedule M Compliance
Project
-
Facility Assessment
-
Documentation Prepared
-
Application Supported
-
Claim Support Provided
Why Choose UPLIFT Financial
Not all consultancy approaches are the same. Pharmaceutical projects often require industry-specific understanding, structured planning, and continuous guidance throughout the journey.
Generic consultants
Pharma-focused consultancy
Reactive support
Project-first planning
Limited engagement
End-to-end assistance till the realization of funds in account
Transaction-based
Long-term advisory approach
RPTUAS Assisted Process Flow
Assessment
Eligibility
Documentation
Application
TC
SSC
Sanction
Claim
Disbursement
Frequently Asked Questions
Have questions about the RPTUAS scheme, eligibility, or project readiness assessments? Find quick answers here.
Yes. Existing pharmaceutical units planning modernization, expansion, or Schedule M upgradation can benefit from project readiness assessments and strategic advisory support.
Every project is different. We can review your current project stage, documentation status, and provide guidance on the most appropriate next steps.
Yes. We can assess your current position and provide support related to documentation review, project readiness, and subsequent stages of the process.
No. UPLIFT provides support beyond documentation, including project planning, strategic guidance, readiness assessment, execution support, and end-to-end advisory assistance.
Early assessment helps identify potential challenges, improve project readiness, support better planning, and reduce uncertainty during later stages of implementation.